AstraZeneca (NYSE:AZN) inks an agreement with
Europe’s Inclusive Vaccines Alliance, led by Germany, France, Italy and
the Netherlands, under which the company will supply up to 400M doses
of Oxford University’s COVID-19 vaccine, currently dubbed ADZ1222
(originally ChAdOx1 nCoV-19), beginning in late Q4 at no profit.
AZN recently signed deals in the UK, U.S. and with
CEPI and Gavi the Vaccine Alliance to supply 700M doses in addition to a
deal with the Serum Institute of India to supply IB doses to low- and
middle-income countries.
Manufacturing costs will be offset by government funding.
A Phase 2/3 trial in the UK launched last month.
AZN’s 2020 financial guidance remains unchanged.
https://seekingalpha.com/news/3582828-astrazeneca-to-supply-up-to-400m-doses-of-covid-vaccine-no-profit
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.